Sanofi EBITDA 2010-2023 | SNY

Sanofi annual and quarterly EBITDA history from 2010 to 2023. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Sanofi EBITDA for the quarter ending December 31, 2023 was $1.376B, a 34.07% decline year-over-year.
  • Sanofi EBITDA for the twelve months ending December 31, 2023 was $9.594B, a 10.51% decline year-over-year.
  • Sanofi 2023 annual EBITDA was $14.78B, a 3.18% increase from 2022.
  • Sanofi 2022 annual EBITDA was $14.324B, a 3.72% increase from 2021.
  • Sanofi 2021 annual EBITDA was $13.81B, a 32.95% decline from 2020.
Sanofi Annual EBITDA
(Millions of US $)
2023 $14,780
2022 $14,324
2021 $13,810
2020 $20,597
2019 $15,616
2018 $11,286
2017 $11,236
2016 $11,245
2015 $11,786
2014 $13,555
2013 $15,605
2012 $14,858
2011 $18,179
2010 $17,307
2009 $17,891
Sanofi Quarterly EBITDA
(Millions of US $)
2023-12-31 $1,376
2023-09-30 $3,502
2023-06-30 $2,039
2023-03-31 $2,676
2022-12-31 $2,087
2022-09-30 $4,309
2022-06-30 $1,634
2022-03-31 $2,691
2021-09-30 $3,580
2021-03-31 $2,527
2020-09-30 $2,927
2020-03-31 $2,338
2019-09-30 $2,516
2019-03-31 $1,538
2018-03-31 $1,549
2017-12-31 $1,188
2017-09-30 $2,434
2017-06-30 $1,596
2017-03-31 $1,851
2016-12-31 $1,842
2016-09-30 $2,722
2016-06-30 $1,724
2016-03-31 $1,305
2015-09-30 $2,308
2015-06-30 $2,131
2014-06-30 $1,977
2013-06-30 $1,545
2012-06-30 $5,370
2012-03-31 $2,582
2011-12-31 $2,047
2011-09-30 $2,184
2011-06-30 $1,596
2011-03-31 $3,061
2010-12-31 $1,360
2010-09-30 $2,954
2010-06-30 $2,940
2010-03-31 $1,961
2009-12-31 $1,057
2009-09-30 $2,874
2009-06-30 $2,908
2009-03-31 $1,973
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $122.796B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $767.386B 110.91
Novo Nordisk (NVO) Denmark $610.484B 46.91
Johnson & Johnson (JNJ) United States $353.710B 14.05
Merck (MRK) United States $327.973B 59.67
AbbVie (ABBV) United States $277.347B 14.33
AstraZeneca (AZN) United Kingdom $243.511B 21.17
Novartis AG (NVS) Switzerland $205.483B 14.57
Pfizer (PFE) United States $163.651B 20.34
Innoviva (INVA) United States $0.985B 6.92